Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead Sciences Inc GILD
News
ITOC Stock Drop - Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against iTonic Holdings Ltd.
Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Did You Lose Money Investing in iTonic Holdings Ltd.? Robbins LLP Urges Investors With Significant Losses to Contact the Firm for Information About Their Rights Against ITOC
Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here.
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 — Data Talk
Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
United States